Kang J H, Ko H M, Moon J S, Yoo H I, Jung J Y, Kim M S, Koh J T, Kim W J, Kim S H
Dental Science Research Institute, School of Dentistry, Chonnam National University, Gwangju, Korea.
Department of Microbiology, College of Medicine, Seonam University, Namwon, Korea;
J Dent Res. 2014 Nov;93(11):1116-23. doi: 10.1177/0022034514552677. Epub 2014 Sep 25.
Osteoprotegerin (OPG) is secreted by stromal and osteoblastic lineage cells and inhibits osteoclastogenesis by preventing the interaction of receptor activator of nuclear factor-κB ligand (RANKL) with receptor activator of nuclear factor-κB (RANK). In this study, the expression of OPG in osteoclasts themselves and its biological functions during osteoclastogenesis were investigated for the first time. OPG expression in vivo in the developing rat maxilla was examined by immunofluorescence analysis. OPG expression in osteoclasts during in vitro osteoclastogenesis was determined by reverse-transcription polymerase chain-reaction (RT-PCR), Western blot, and immunofluorescence staining. We determined the function of OPG produced by osteoclasts during osteoclastogenesis by silencing the OPG gene. The effects of OPG on bone-resorbing activity and apoptosis of mature osteoclasts were examined by the assay of resorptive pit formation on calcium-phosphate-coated plate and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, respectively. In the immunofluorescence findings, strong immunoreactivities were unexpectedly seen in multinucleated tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts around the growing and erupting tooth germs in the rat alveolar bone. In vitro, OPG expression was significantly increased during the differentiation of osteoclasts from mouse bone-marrow-derived cells treated with a combination of macrophage colony-stimulating factor (M-CSF) and RANKL. Interestingly, it was found that OPG small interfering (si)RNA treatment during osteoclastogenesis enhanced the sizes of osteoclasts, but attenuated their bone-resorbing activity. Also, the increased chromosomal DNA fragmentation and caspase-3 activity in the late phase of osteoclastogenesis were found to be decreased by treatment with OPG siRNA. Furthermore, effects of OPG siRNA treatment on osteoclastogenesis and bone-resorbing activity were recovered by the treatment of exogenous OPG. These results suggest that OPG, expressed by the osteoclasts themselves, may play an auto-regulatory role in the late phase of osteoclastogenesis through the induction of apoptosis.
骨保护素(OPG)由基质细胞和成骨细胞系细胞分泌,通过阻止核因子κB受体激活剂配体(RANKL)与核因子κB受体激活剂(RANK)相互作用来抑制破骨细胞生成。在本研究中,首次对破骨细胞自身中OPG的表达及其在破骨细胞生成过程中的生物学功能进行了研究。通过免疫荧光分析检测发育中大鼠上颌骨中OPG的体内表达。通过逆转录聚合酶链反应(RT-PCR)、蛋白质印迹法和免疫荧光染色确定体外破骨细胞生成过程中破骨细胞中OPG的表达。我们通过沉默OPG基因来确定破骨细胞在破骨细胞生成过程中产生的OPG的功能。分别通过在磷酸钙包被板上进行吸收陷窝形成测定和末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)染色,检测OPG对成熟破骨细胞骨吸收活性和凋亡的影响。在免疫荧光结果中,在大鼠牙槽骨中生长和萌出的牙胚周围的多核抗酒石酸酸性磷酸酶(TRAP)阳性破骨细胞中意外地观察到强免疫反应性。在体外,在用巨噬细胞集落刺激因子(M-CSF)和RANKL组合处理的小鼠骨髓来源细胞的破骨细胞分化过程中,OPG表达显著增加。有趣的是,发现在破骨细胞生成过程中进行OPG小干扰(si)RNA处理可增大破骨细胞的大小,但减弱其骨吸收活性。此外,发现用OPG siRNA处理可降低破骨细胞生成后期增加的染色体DNA片段化和半胱天冬酶-3活性。此外,外源性OPG处理可恢复OPG siRNA处理对破骨细胞生成和骨吸收活性的影响。这些结果表明,破骨细胞自身表达的OPG可能通过诱导凋亡在破骨细胞生成后期发挥自调节作用。